Number
Percentage
Patients
100
AGE OF THE SUBJECTS
Age <45
36
36%
Age >45
64
64%
GENDER OF THE SUBJECTS
Males
65
65%
Female
35
35%
STAGE OF THE DISEASE
CP-CML
48
48%
AP-CML
28
28%
BC-CML
24
24%
TYPE OF BCR-ABL TRANSCRIPTS
A2b2
31
31%
A2B3
67
67%
A2b2/ A2b3
2
2%
MOLECULAR RESPONSES TO IMATINIB
MMR
52
52%
No MR
HEMATOLOGICAL RESPONSES TO IMATINIB
MHR
50
50%
Minor HR
10
10%
Loss HR
40
40%
TYROSINE KINASE INHIBITOR THERAPY
Imatinib
90
90%
7
7%
Interferon
3
3%
THROMBOCYTOPENIA
Thrombocytopenia
60
60%
No Thrombocytopenia